About 1,460 results
Lilly launches telehealth option for obesity and other drugs
3 days ago · Eli Lilly has launched a new website-based access programme for some drugs like its new obesity therapy Zepbound, opening up a new direct-to-consumer (DTC) channel that …
See results only from pharmaphorum.comLilly adds another sales chan…
Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy …
Lilly launches single-dose Ze…
Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity …
Eli Lilly logs massive Q4 revenue jump—but it's not just thanks to ...
6 days ago · Eli Lilly Mounjaro Zepbound GLP-1. Thanks to impressive sales growth across multiple therapeutic areas in 2024, Eli Lilly seems to have assuaged investor concerns that its …
Lilly adds another sales channel for obesity drug Zepbound
2 days ago · Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy Zepbound in an expansion of the ways patients with a prescription can access the drug.
Lilly launches single-dose Zepbound to ease self-pay access
3 days ago · Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of …
Lilly's new focus: Using incretin therapies in neuro, immunology
6 days ago · Eli Lilly's approved incretin therapy is tirzepatide, an injectable dual GLP-1 and GIP receptor sold as Mounjaro for diabetes and Zepbound for weight loss and, most recently, …
Lilly Exec Says U.S. Zepbound Performance Is Going Very Well
5 days ago · Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating …
Lilly's Mounjaro and Zepbound contribute to big revenue boost ...
6 days ago · Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 …
LLY's Q4 Earnings Beat, Mounjaro, Zepbound Sales Fall Shy of
5 days ago · Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks Consensus Estimate of $5.03 per share. Earnings rose …
Zepbound sales double, tariffs could hit Ozempic, Pfizer on
5 days ago · Zepbound sales keep soaring, even as weight loss drug growth slows List slides An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on …
Eli Lilly Q4 2024 Financial Analysis and 2025 Outlook
3 days ago · Eli Lilly & Co. has delivered a strong performance in Q4 2024, with revenue surging 45% year-over-year to $13.53 billion. This growth was primarily driven by its blockbuster …
